EPCAM and prostate carcinoma: However, given the heterogeneity in EpCAM expression for patients with castration-resistant prostate cancer (Figure 9B), the use of EpCAM as a sole biomarker for CTC detection poses some concerns about the detection of PCa cells that express little to no epithelial markers following EMT.